Novartis AG
SWXNovartis heads into the second week of June down 4.6% on the week, closing at CHF 113.00 — yet today's news flow is pulling hard in the other direction. The week's sharpest tension is the gap between a softening share price and a genuinely meaningful clinical catalyst. Today, Novartis published Phase III REPLENISH data for Cosentyx in the New England Journal of Medicine, showing…
NOVN cost to borrow surges to 1.89% — up 191% in one week from 0.65%, signaling acute scarcity of borrowable shares.
Snapshot as of 22 Jun 2026
A new long-form analysis for NOVN this week — anomalies vs the company's own history, peer comparisons, news context, and the full data picture. Premium subscribers only.
Read on ORTEX →Sign up for premiumNovartis heads into the second week of June down 4.6% on the week, closing at CHF 113.00 — yet today's news flow is pulling hard in the other direction. The week's sharpest tension is the gap between a softening share…
NOVN enters the week down 8% over the past month, closing Tuesday at CHF 113.54. The most striking tension here is the gap between insider behaviour — persistent and sizeable selling — and an analyst community that…
NOVN arrives at its Q1 2026 results today with one of the most striking setup features being the near-complete retreat of short sellers over the past six weeks. Short interest has collapsed. The SI % of free float has…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for NOVN — free to start on ORTEX.
Sign up for free →Open NOVN on ORTEX